Cox Capital Mgt LLC Decreases Stake in Abbott Laboratories $ABT

Cox Capital Mgt LLC cut its stake in shares of Abbott Laboratories (NYSE:ABT) by 41.4% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 16,554 shares of the healthcare product maker’s stock after selling 11,694 shares during the period. Cox Capital Mgt LLC’s holdings in Abbott Laboratories were worth $1,502,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Cornerstone Financial Management LLC acquired a new position in Abbott Laboratories during the 4th quarter worth approximately $25,000. MidAtlantic Capital Management Inc. acquired a new stake in shares of Abbott Laboratories in the 4th quarter valued at $25,000. Purpose Unlimited Inc. purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth $25,000. Portfolio Resources Advisor Group Inc. purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth $26,000. Finally, Abound Financial LLC acquired a new position in shares of Abbott Laboratories during the fourth quarter worth $26,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Wolfe Research upgraded Abbott Laboratories (ABT) from “peer perform” to “outperform” and set a $130 target, implying substantial upside from recent trading levels. Benzinga analyst upgrade report
• Positive Sentiment: Abbott’s Established Pharmaceutical Products division is benefiting from emerging-market growth, broad branded-generic offerings and resilient healthcare demand. Expanding biosimilar opportunities could provide an additional long-term growth avenue. Zacks EPD growth report
• Positive Sentiment: Abbott and Google Health announced a multiyear partnership to integrate Abbott’s Lingo continuous glucose-monitoring data into Google’s AI-powered consumer health tools. The collaboration could increase Lingo’s visibility, support personalized metabolic-health services and generate valuable real-world data. Abbott and Google Health Lingo partnership
• Positive Sentiment: Bank of America Securities issued a “buy” recommendation for ABT, reinforcing the constructive Wall Street view. Bank of America buy rating
• Neutral Sentiment: Abbott’s stock outperformed competitors during a strong broader trading session, reflecting market momentum but not a new company-specific fundamental catalyst. MarketWatch trading report
• Neutral Sentiment: Abbott’s PULSE study is evaluating earlier treatment for atrial fibrillation. Positive clinical results could expand future device demand, but the study remains ongoing and carries execution and clinical risk. TipRanks PULSE study report
• Neutral Sentiment: Abbott renewed its blood-donation campaign with the Big Ten amid a U.S. blood shortage. The initiative supports Abbott’s brand and blood-management business, though its direct near-term financial impact is likely limited. Abbott and Big Ten blood donation campaign

Wall Street Analyst Weigh In

A number of research firms have weighed in on ABT. JPMorgan Chase & Co. raised their price target on Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Daiwa Securities Group cut Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price objective for the company. in a research report on Wednesday, April 22nd. Oppenheimer cut their target price on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. UBS Group lowered their price target on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a report on Tuesday, July 28th. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $130.00 price objective on shares of Abbott Laboratories in a report on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average price target of $118.67.

Abbott Laboratories Stock Up 0.4%

ABT opened at $111.37 on Friday. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The stock has a market capitalization of $192.71 billion, a P/E ratio of 36.04, a price-to-earnings-growth ratio of 2.15 and a beta of 0.59. The business’s 50-day simple moving average is $97.27 and its 200-day simple moving average is $99.75.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The firm had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business’s revenue was up 13.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.